Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan L Cohn

Showing results (161-170 of 183) with videos related to

Pageof 19
Sort By:
The Lancet. Oncology|December 9, 2019
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trialBirgit Geoerger, Hyoung Jin Kang, Michal Yalon-Oren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II studySuzanne Shusterman, Wendy B London, Stephen D Gillies, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2021
Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032Alice L Yu, Andrew L Gilman, M Fevzi Ozkaynak, et al.
Pediatric Blood & Cancer|April 11, 2019
Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 studySteve E Braunstein, Wendy B London, Susan G Kreissman, et al.
JCO Clinical Cancer Informatics|October 18, 2021
Pediatric Cancer Data Commons: Federating and Democratizing Data for Childhood Cancer ResearchAlejandro Plana, Brian Furner, Monica Palese, et al.
Molecular Oncology|February 25, 2014
Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter™ systemThomas P Stricker, Andres Morales La Madrid, Alexandre Chlenski, et al.
Journal of Pediatric Oncology Nursing : Official Journal of the Association of Pediatric Oncology Nurses|July 8, 2016
Patient/Family Education for Newly Diagnosed Pediatric Oncology PatientsWendy Landier, JoAnn Ahern, Lamia P Barakat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2015
Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory NeuroblastomaSteven G DuBois, Susan Groshen, Julie R Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2019
Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531Clare J Twist, Mary Lou Schmidt, Arlene Naranjo, et al.
Journal of Pediatric Surgery|September 24, 2024
Evaluation of Image-Defined Risk Factor (IDRF) Assessment in Patients With Intermediate-risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531Erin G Brown, E Stanton Adkins, Peter Mattei, et al.
Pageof 19

Showing results (161-170 of 183) with videos related to

Sort By:
Pageof 19
The Lancet. Oncology|December 9, 2019
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trialBirgit Geoerger, Hyoung Jin Kang, Michal Yalon-Oren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II studySuzanne Shusterman, Wendy B London, Stephen D Gillies, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2021
Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032Alice L Yu, Andrew L Gilman, M Fevzi Ozkaynak, et al.
Pediatric Blood & Cancer|April 11, 2019
Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 studySteve E Braunstein, Wendy B London, Susan G Kreissman, et al.
JCO Clinical Cancer Informatics|October 18, 2021
Pediatric Cancer Data Commons: Federating and Democratizing Data for Childhood Cancer ResearchAlejandro Plana, Brian Furner, Monica Palese, et al.
Molecular Oncology|February 25, 2014
Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter™ systemThomas P Stricker, Andres Morales La Madrid, Alexandre Chlenski, et al.
Journal of Pediatric Oncology Nursing : Official Journal of the Association of Pediatric Oncology Nurses|July 8, 2016
Patient/Family Education for Newly Diagnosed Pediatric Oncology PatientsWendy Landier, JoAnn Ahern, Lamia P Barakat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2015
Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory NeuroblastomaSteven G DuBois, Susan Groshen, Julie R Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2019
Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531Clare J Twist, Mary Lou Schmidt, Arlene Naranjo, et al.
Journal of Pediatric Surgery|September 24, 2024
Evaluation of Image-Defined Risk Factor (IDRF) Assessment in Patients With Intermediate-risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531Erin G Brown, E Stanton Adkins, Peter Mattei, et al.
Pageof 19